Highlights From NCCN

Updates to NCCN Guidelines for Multiple Myeloma: Recently Approved First-Line Treatments for Patients With NDMM Eligible and Ineligible for Transplant
Evolving Landscapes in Multiple Myeloma, NCCN Guidelines, Highlights From NCCN, Multiple Myeloma
Web Exclusives
Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma.
NCCN Guidelines: Updates from Recent FDA Approvals for Sacituzumab Govitecan-hziy
Breast Cancer, NCCN Guidelines, Highlights From NCCN
2021 Year in Review - Triple-Negative Breast Cancer
Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
By Matthew A. Gubens, MD, MS
Lung Cancer, Highlights From NCCN, NCCN Guidelines
December 2019 Vol 10, No 12
The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Leukemia & Lymphoma, NCCN Guidelines, Highlights From NCCN
May 2019 Vol 10, No 5
The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.
Germline Testing, Molecular Profiling Now Recommended in NCCN Pancreatic Cancer Guideline
Genetics & Genomics, NCCN Guidelines, Highlights From NCCN
May 2019 Vol 10, No 5
Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of pancreatic cancer.
New Targeted Combination Therapies in NCCN Guideline for CRC Attack Various Pathways
Colorectal Cancer, NCCN Guidelines, Highlights From NCCN
May 2019 Vol 10, No 5
More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
Highlights From NCCN, NCCN Guidelines
September 2018 Vol 9, No 9
The delivery and receipt of cancer care in value-based healthcare models was the subject of a roundtable discussion at the National Comprehensive Cancer Network (NCCN) 23rd Annual Conference.
Updated Colon and Rectal Cancer Guidelines Include Options for Surveillance and Shortened Duration of Adjuvant Treatment
Conference Correspondent, Highlights From NCCN
May 2018 Vol 9, No 5
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.

Page 1 of 2

Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?